The Library
Left ventricular hypertrophy in diabetic cardiomyopathy : a target for intervention
Tools
Mohan, Mohapradeep, Dihoum, Adel, Mordi, Ify R., Choy, Anna-Maria, Rena, Graham and Lang, Chim C. (2021) Left ventricular hypertrophy in diabetic cardiomyopathy : a target for intervention. Frontiers in Cardiovascular Medicine, 8 . doi:10.3389/fcvm.2021.746382 ISSN 2297-055X.
|
PDF
WRAP-left-ventricular-hypertrophy-diabetic-cardiomyopathy-target-intervention-Mohan-2021.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (744Kb) | Preview |
Official URL: http://dx.doi.org/10.3389/fcvm.2021.746382
Abstract
Heart failure is an important manifestation of diabetic heart disease. Before the development of symptomatic heart failure, as much as 50% of patients with type 2 diabetes mellitus (T2DM) develop asymptomatic left ventricular dysfunction including left ventricular hypertrophy (LVH). Left ventricular hypertrophy (LVH) is highly prevalent in patients with T2DM and is a strong predictor of adverse cardiovascular outcomes including heart failure. Importantly regression of LVH with antihypertensive treatment especially renin angiotensin system blockers reduces cardiovascular morbidity and mortality. However, this approach is only partially effective since LVH persists in 20% of patients with hypertension who attain target blood pressure, implicating the role of other potential mechanisms in the development of LVH. Moreover, the pathophysiology of LVH in T2DM remains unclear and is not fully explained by the hyperglycemia-associated cellular alterations. There is a growing body of evidence that supports the role of inflammation, oxidative stress, AMP-activated kinase (AMPK) and insulin resistance in mediating the development of LVH. The recognition of asymptomatic LVH may offer an opportune target for intervention with cardio-protective therapy in these at-risk patients. In this article, we provide a review of some of the key clinical studies that evaluated the effects of allopurinol, SGLT2 inhibitor and metformin in regressing LVH in patients with and without T2DM.
Item Type: | Journal Article | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Subjects: | Q Science > QP Physiology R Medicine > RB Pathology R Medicine > RC Internal medicine |
|||||||||
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences > Mental Health and Wellbeing Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
|||||||||
Library of Congress Subject Headings (LCSH): | Myocardium -- Diseases, Diabetes -- Complications, Heart failure , Non-insulin-dependent diabetes -- Treatment, Metformin, Xanthine oxidase -- Inhibitors, Heart -- Hypertrophy, Heart -- Left ventricle -- Hypertrophy | |||||||||
Journal or Publication Title: | Frontiers in Cardiovascular Medicine | |||||||||
Publisher: | Frontiers Media | |||||||||
ISSN: | 2297-055X | |||||||||
Official Date: | 29 September 2021 | |||||||||
Dates: |
|
|||||||||
Volume: | 8 | |||||||||
DOI: | 10.3389/fcvm.2021.746382 | |||||||||
Status: | Peer Reviewed | |||||||||
Publication Status: | Published | |||||||||
Access rights to Published version: | Open Access (Creative Commons) | |||||||||
Date of first compliant deposit: | 20 October 2021 | |||||||||
Date of first compliant Open Access: | 21 October 2021 | |||||||||
RIOXX Funder/Project Grant: |
|
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |
Downloads
Downloads per month over past year